TITLE

Precious Mettle

AUTHOR(S)
Comer, Benjamin
PUB. DATE
July 2011
SOURCE
Pharmaceutical Executive;Jul2011, Vol. 31 Issue 7, p28
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article highlights the role of Tony Coles as chief executive officer (CEO) at Onyx Pharmaceuticals Inc. in leading the company to greater heights in the U.S. It recounts how the condition of his son having a compromising mediastinal mass has influenced his craft in discovering new compounds, both in small and large molecules. Moreover, his contributions on the next-generation breakthrough cancer product calfilzomib, aside from the its prime asset Nevaxar, are also emphasized.
ACCESSION #
64413351

 

Related Articles

  • COMPANY SPOTLIGHT - Onyx Pharmaceuticals, Inc.  // PharmaWatch: Cancer;Nov2009, Vol. 8 Issue 11, p24 

    The article presents a company profile for Onyx Pharmaceuticals Inc., a U.S.-based biopharmaceutical company engaged in research and development of drugs for cancer treatment. Nexavar or sorafenib, a kinase and angiogenesis inhibitor for targeting signal pathways for the proliferation of cancer...

  • Pharmaceutical sector sees flurry of acquisitions.  // Chain Drug Review;9/9/2013, Vol. 35 Issue 14, p13 

    The article offers information on several acquisitions in the U.S. pharmaceutical industry including the purchase of Onyx Pharmaceuticals Inc. by Amgen Inc., acquisition of Hi-Tech Pharmacal Co. by Akorn Inc. and purchase of Amplimmune Inc. by AstraZeneca PLC.

  • Start anywhere, ask questions and fail early. Arnold, Matthew // Medical Marketing & Media;May2010, Vol. 45 Issue 5, p28 

    The article presents the insights of chief executive officers (CEOs) on the future of the pharmaceutical industry in the U.S.

  • EARNINGS ROUNDUP.  // BioWorld Today;5/8/2008, Vol. 19 Issue 90, p2 

    This section offers news briefs concerning the U.S. biopharmaceutical industry. Emergent BioSolutions, Inc. has posted increased revenues and a net income of $7 million or 24 cents per share for the first quarter of 2008. The total sales generated by Onyx Pharmaceuticals, Inc. for its Nexavar...

  • Cancer News Round-up.  // PharmaWatch: Monthly Review;Sep2006, Vol. 5 Issue 9, p4 

    The article reports developments in the pharmaceutical industry worldwide from July 15, 2005 to August 14, 2006. The drugs for the treatment of kidney cancer and renal cell carcinoma from Pfizer Inc. and Bayer AG and Onyx Pharmaceuticals Inc. have gained approval to be sold in Europe. Pfizer's...

  • RESEARCH & TECHNOLOGY.  // MondayMorning;8/2/2010, Vol. 18 Issue 29, p4 

    The article presents news brief related to the drug industry. Allos Therapeutics Inc. reports that its lung-cancer drug Folotyn increased survival of patients, however, the lower sales raised concern about the marketing opportunity. A study revealed that prostate cancer vaccine Provenge...

  • Onyx Raises $185 Million On Nexavar Data In Liver Cancer. Morrison, Trista // BioWorld Today;6/22/2007, Vol. 18 Issue 121, p1 

    The article reports that Onyx Pharmaceuticals Inc. is raising $185 million in response to the positive prospects of its kidney cancer drug Nexavar. Onyx will be offering 6.6 million shares at $28 per share in a transaction managed and underwritten by Morgan Stanley & Co. Inc. and Merrill Lynch &...

  • Onyx's Shares Plummeted on NSCLC Data.  // Bioworld Week;2/25/2008, Vol. 16 Issue 8, p2 

    The article reports on the 26.4% drop of shares of Emeryville, California-based Onyx Pharmaceuticals Inc. due to the termination of the Phase III study of Nexavar, a non-small-cell lung cancer drug. It notes that the termination of the trial is associated with the lack of efficacy of the...

  • CREATIVE COMPETITION.  // Smart Business Northern California;Jul2011, Vol. 4 Issue 8, ps16 

    The article profiles Dr. N. Anthony Coles, president and chief executive officer (CEO) at Onyx Pharmaceuticals Inc. and a finalist of the Ernst & Young Entrepreneur of the Year Award in the life sciences category in Northern California.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics